<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103401</url>
  </required_header>
  <id_info>
    <org_study_id>VGH-EYE02</org_study_id>
    <nct_id>NCT01103401</nct_id>
  </id_info>
  <brief_title>Ketorolac Plus Tobramycin/Dexamethasone Versus Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery</brief_title>
  <official_title>Ketorolac Plus Tobramycin/Dexamethasone vs. Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veroia General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veroia General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial compares two regimens of topical therapy:

        -  tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day

        -  combination of tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four
           times/day, plus Ketorolac tromethamine 0.5% (Acular®, Allergan), one drop three
           times/day.

      Patients are independently assessed by two ophthalmologists. On days 7,14,21,28 patients are
      evaluated for

        -  corneal edema

        -  conjunctival hyperemia

        -  anterior chamber (Tyndall) reaction.

      The investigators purpose was to evaluate the benefit of adding a non-steroid agent to an
      antibiotic/steroid combination after uneventful phacoemulsification. Adopting a weekly
      follow-up, to gain insight into the optimal duration of postoperative treatment and to
      examine whether risk factors for inflammation exist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomized to: i) tobramycin 0.3% - dexamethasone 0.1% one drop qid (TD group,
      n=72, 28 days) and ii) combination of tobramycin 0.3% - dexamethasone 0.1%, one drop qid,
      plus Ketorolac tromethamine 0.5%, one drop tid (TD-K group, n=73, 28 days). Patients
      undergoing vitrectomy due to posterior capsule rupture were excluded. On days 7, 14, 21, 28,
      the frequency of inflammation-related signs [corneal edema, conjunctival hyperemia, anterior
      chamber (Tyndall) reaction], as well as the best corrected visual acuity (BCVA) were
      measured. On day 21, logistic regression was performed to evaluate risk factors for
      inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity, corneal edema, Tyndall reaction, redness</measure>
    <time_frame>1,7,14,28 post-operative day, Up to 28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Tobramycin/Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobramycin/Dexamethasone plus Ketorolac tromethamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Tobramycin 0.3% - Dexamethasone 0.1%</intervention_name>
    <description>one drop four times per day</description>
    <arm_group_label>Tobramycin/Dexamethasone</arm_group_label>
    <arm_group_label>Tobramycin/Dexamethasone plus Ketorolac tromethamine</arm_group_label>
    <other_name>Tobradex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine</intervention_name>
    <description>Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day</description>
    <arm_group_label>Tobramycin/Dexamethasone</arm_group_label>
    <arm_group_label>Tobramycin/Dexamethasone plus Ketorolac tromethamine</arm_group_label>
    <other_name>Acular</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  phacoemulsification (due to cataract)

          -  uneventful phacoemulsification surgery

        Exclusion Criteria:

          -  history of intraocular surgery in the operated eye,

          -  any previous episode of uveitis in the operated eye,

          -  severe systemic disease (heart failure NYHA stage III of IV, end-stage renal failure,
             pulmonary failure, patients receiving chemotherapy),

          -  regular, systemic use of steroid or non-steroid anti-inflammatory drugs during the
             last three months

          -  disruption of the anterior lens capsule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonidas E Papazisis, Director</last_name>
    <role>Study Director</role>
    <affiliation>leopapazisis@yahoo.gr</affiliation>
  </overall_official>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <name_title>Department of Ophthalmology</name_title>
    <organization>Veroia General Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

